JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Chiusa

73.59 -1.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

73.52

Massimo

73.74

Metriche Chiave

By Trading Economics

Entrata

-923M

2.5B

Vendite

1B

15B

P/E

Media del settore

27.832

34.393

Rendimento da dividendi

2.12

Margine di Profitto

16.947

Dipendenti

94,300

EBITDA

-18M

5B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.44% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.12%

2.54%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

5.1B

231B

Apertura precedente

74.9

Chiusura precedente

73.59

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

AstraZeneca PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 lug 2025, 08:08 UTC

Utili

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 lug 2025, 06:46 UTC

Utili

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8 ago 2025, 10:51 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 ago 2025, 11:10 UTC

Azioni calde

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 lug 2025, 11:02 UTC

Utili

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 lug 2025, 11:02 UTC

Utili

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 lug 2025, 11:01 UTC

Utili

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 lug 2025, 11:00 UTC

Utili

AstraZeneca Results: H1 and Q2 2025

29 lug 2025, 08:00 UTC

Discorsi di Mercato
Utili

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 lug 2025, 07:53 UTC

Discorsi di Mercato
Utili

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 lug 2025, 07:26 UTC

Discorsi di Mercato
Utili

AstraZeneca Shares Look Undervalued -- Market Talk

29 lug 2025, 06:03 UTC

Utili

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 lug 2025, 06:03 UTC

Utili

AstraZeneca 2Q Total Revenue $14.46B

29 lug 2025, 06:03 UTC

Utili

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 lug 2025, 06:03 UTC

Utili

AstraZeneca 2Q Core EPS $2.17

29 lug 2025, 06:02 UTC

Utili

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 lug 2025, 06:02 UTC

Utili

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 lug 2025, 06:02 UTC

Utili

AstraZeneca Backs 2025 View

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q Rev $14.46B

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q Adj EPS $2.17

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q Net Pft $2.45B

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q Oper Pft $3.51B

29 lug 2025, 06:00 UTC

Utili

AstraZeneca PLC 2Q EPS $1.57

28 lug 2025, 10:51 UTC

Discorsi di Mercato

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 lug 2025, 10:19 UTC

Discorsi di Mercato

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 lug 2025, 09:34 UTC

Azioni calde

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 lug 2025, 10:59 UTC

Discorsi di Mercato

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 lug 2025, 09:17 UTC

Azioni calde

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New -2-

Confronto tra pari

Modifica del prezzo

AstraZeneca PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

26.44% in crescita

Previsioni per 12 mesi

Media 93 USD  26.44%

Alto 97 USD

Basso 85 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AstraZeneca PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 69.55Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.